Blue Bell Private Wealth Management’s Iterum Therapeutics ITRM Stock Holding History

Blue Bell Private Wealth Management’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-66	Closed	-$2	–	740
2026 Q1	$2	Hold	66	–	–	﹤0.01%	724
2025 Q4	$22	Hold	66	–	–	﹤0.01%	725
2025 Q3	$44	Hold	66	–	–	﹤0.01%	729
2025 Q2	$66	Hold	66	–	–	﹤0.01%	722
2025 Q1	$81	Hold	66	–	–	﹤0.01%	714
2024 Q4	$117	Hold	66	–	–	﹤0.01%	668
2024 Q3	$72	Hold	66	–	–	﹤0.01%	682
2024 Q2	$76	Hold	66	–	–	﹤0.01%	711
2024 Q1	$102	Buy	+66	New	+$107	﹤0.01%	718
2022 Q3	–	Sell	-67	Closed	–	–	787
2022 Q2	$0	Hold	67	–	–	﹤0.01%	845
2022 Q1	$0	Hold	67	–	–	﹤0.01%	897
2021 Q4	$0	Buy	+67	New	+$517	﹤0.01%	849

Other funds holding ITRM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

CCMW

Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

Blue Bell Private Wealth Management's ITRM Position: Q2 2026 in Review

Blue Bell Private Wealth Management sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 66 shares — an estimated $2 sold.

Blue Bell Private Wealth Management first reported a position in ITRM in Q4 2021 and held it in 12 quarters. The position peaked at $117 in Q4 2024. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

Blue Bell Private Wealth Management reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
Blue Bell Private Wealth Management sold 66 Iterum Therapeutics shares in Q2 2026, an estimated $2.
Blue Bell Private Wealth Management first reported a position in Iterum Therapeutics in Q4 2021 and held it in 12 quarters.
Blue Bell Private Wealth Management's Iterum Therapeutics position peaked at $117 in Q4 2024.
2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on Blue Bell Private Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.